

Hyung Joon Yim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284667/publications.pdf>

Version: 2024-02-01

69
papers

2,665
citations

331259

21
h-index

189595

50
g-index

69
all docs

69
docs citations

69
times ranked

2703
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Terlipressin-induced hyponatremic seizure. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 501-504. | 0.6 | 480 |
| 2 | Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. <i>Hepatology</i> , 2006, 43, S173-S181. | 3.6 | 457 |
| 3 | Evolution of multi-drug resistant hepatitis B virus during sequential therapy. <i>Hepatology</i> , 2006, 44, 703-712. | 3.6 | 238 |
| 4 | Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. <i>Hepatology</i> , 2014, 60, 954-963. | 3.6 | 169 |
| 5 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2015, 50, 445-454. | 2.3 | 121 |
| 6 | Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 319-330. | 4.5 | 88 |
| 7 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478. | 1.1 | 88 |
| 8 | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). <i>Oncolmmunology</i> , 2019, 8, 1615817. | 2.1 | 85 |
| 9 | Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429. | 4.5 | 66 |
| 10 | A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 373-382. | 1.1 | 55 |
| 11 | Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 292-299. | 1.4 | 49 |
| 12 | Current management of hepatocellular carcinoma: An Eastern perspective. <i>World Journal of Gastroenterology</i> , 2015, 21, 3826. | 1.4 | 48 |
| 13 | Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204. | 1.9 | 43 |
| 14 | Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 1071-1079. | 1.9 | 33 |
| 15 | Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Gut and Liver</i> , 2021, 15, 284-294. | 1.4 | 33 |
| 16 | Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. <i>Liver International</i> , 2012, 32, 656-664. | 1.9 | 32 |
| 17 | Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 195. | 4.5 | 27 |
| 18 | Serum aminotransferase levels instead of etiology affects the accuracy of transient elastography in chronic viral hepatitis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 492-500. | 1.4 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1838-1842. | 1.4 | 25 |
| 20 | Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. <i>Journal of Hepatology</i> , 2022, 77, 967-977. | 1.8 | 25 |
| 21 | Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 503-510. | 1.4 | 24 |
| 22 | Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 540-551. | 1.9 | 22 |
| 23 | Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (<sc>ACE</sc> study): a 2-year follow-up randomized controlled trial. <i>Liver International</i> , 2013, 33, 244-254. | 1.9 | 21 |
| 24 | Long-term Prognosis of Acute-on-Chronic Liver Failure Survivors. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 134-141. | 1.1 | 21 |
| 25 | Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222. | 6.1 | 20 |
| 26 | Comparison of Clevudine and Entecavir for Treatment-naïve Patients With Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 893-899. | 1.1 | 19 |
| 27 | Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 910-917. | 1.4 | 19 |
| 28 | Systemic Cytotoxic Chemotherapy of Patients With Advanced Hepatocellular Carcinoma in the Era of Sorafenib Nonavailability. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, e22-e29. | 1.1 | 18 |
| 29 | Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis. <i>Gut and Liver</i> , 2021, 15, 599-605. | 1.4 | 18 |
| 30 | A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955. | 1.9 | 17 |
| 31 | Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1321-1330. | 1.0 | 17 |
| 32 | Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetylcysteine-D-glucosaminidase. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 234-240. | 1.4 | 17 |
| 33 | Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database. <i>Journal of Korean Medical Science</i> , 2022, 37, e29. | 1.1 | 16 |
| 34 | Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 987-995. | 1.4 | 15 |
| 35 | Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1775-1781. | 1.4 | 15 |
| 36 | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 258. | 0.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. <i>World Journal of Gastroenterology</i> , 2015, 21, 10874. | 1.4 | 14 |
| 38 | Determinants of reâ€compensation in patients with hepatitis B virusâ€related decompensated cirrhosis starting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 83-96. | 1.9 | 13 |
| 39 | Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. <i>Liver International</i> , 2020, 40, 3083-3092. | 1.9 | 11 |
| 40 | Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?. <i>Hepatology International</i> , 2021, 15, 934-945. | 1.9 | 11 |
| 41 | Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429. | 1.4 | 11 |
| 42 | Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients Who Maintained Virologic Response for One Year After Lamivudine Discontinuation. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1572-1577. | 1.1 | 10 |
| 43 | Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 808-816. | 1.1 | 9 |
| 44 | Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2811-2813.e1. | 2.4 | 9 |
| 45 | Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 889-895. | 1.1 | 8 |
| 46 | Levels of Hepatitis B Virus (HBV) Replication During the Nonreplicative Phase: HBV Quantification by Real-Time PCR in Korea. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2403-2409. | 1.1 | 7 |
| 47 | How can we improve the performance of Model for Endâ€Stage Liver Disease sodium score in patients with hepatitis B virusâ€related decompensated liver cirrhosis commencing antiviral treatment?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1641-1648. | 1.4 | 7 |
| 48 | Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060. | 1.0 | 7 |
| 49 | Addition of liver stiffness enhances the predictive accuracy of the PAGEâ€B model for hepatitis Bâ€related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927. | 1.9 | 7 |
| 50 | Endoscopic biliary stent insertion through specialized duodenal stent for combined malignant biliary and duodenal obstruction facilitated by stent or PTBD guidance. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1258-1262. | 0.6 | 7 |
| 51 | Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. <i>Liver International</i> , 2019, 39, 1109-1119. | 1.9 | 6 |
| 52 | <i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 4687-4696. | 1.4 | 6 |
| 53 | Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 745-756. | 0.7 | 6 |
| 54 | Adefovir and Lamivudine Combination Therapy in Patients with Entecavir-Resistant Chronic Hepatitis B: Antiviral Responses and Evolution of Mutations. <i>Intervirology</i> , 2014, 57, 239-247. | 1.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis. <i>Gut and Liver</i> , 2021, 15, 430-439. | 1.4 | 5 |
| 56 | Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. <i>Gut and Liver</i> , 2020, 14, 117-124. | 1.4 | 5 |
| 57 | Risk Factors for Dropout From the Liver Transplant Waiting List of Hepatocellular Carcinoma Patients Under Locoregional Treatment. <i>Transplantation Proceedings</i> , 2018, 50, 3521-3526. | 0.3 | 4 |
| 58 | Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 378-386. | 1.4 | 4 |
| 59 | Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. <i>Journal of Korean Medical Science</i> , 2020, 35, e129. | 1.1 | 4 |
| 60 | Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. <i>Gut and Liver</i> , 2017, 11, 129-135. | 1.4 | 3 |
| 61 | Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 77, 22-29. | 0.2 | 2 |
| 62 | Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1306-1318. | 1.0 | 1 |
| 63 | A case report of a patient presented with skin ulcer after treatment of lenvatinib. <i>Journal of Liver Cancer</i> , 2021, 21, 194-198. | 0.3 | 1 |
| 64 | FIB-4 index and liver fibrosis are risk factors for long-term outcomes in atrial fibrillation-related stroke. <i>Clinical Neurology and Neurosurgery</i> , 2022, 217, 107235. | 0.6 | 1 |
| 65 | A Case of Portopulmonary Hypertension Associated with Primary Biliary Cirrhosis. <i>Tuberculosis and Respiratory Diseases</i> , 2007, 62, 421. | 0.7 | 0 |
| 66 | P123 The effect of necrosis inhibition on acute DSS colitis model of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S154-S155. | 0.6 | 0 |
| 67 | Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event. <i>Journal of Liver Cancer</i> , 2019, 19, 154-158. | 0.3 | 0 |
| 68 | First-line Helicobacter pylori Eradication Rate of the 10-day Hybrid Therapy. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2020, 20, 300-305. | 0.1 | 0 |
| 69 | Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial. <i>Hepatitis Monthly</i> , 2022, 21, . | 0.1 | 0 |